Table 3 TOP 5 KEGG pathways in the PPI of the DPTs of aspirin
From: The targets of aspirin in bladder cancer: bioinformatics analysis
term description | Â | count | strength | false discovery rate | GENE ID |
|---|---|---|---|---|---|
Cell cycle | Â | 23 | 1.77 | 3.61E-31 | CCND1, CDKN1B, CDK4, MDM2, CCND2, CREBBP, CCNE1, CDKN2C, EP300, CDK6, CDK2, RB1, TP53, CCNA2, SKP2, CDKN2B, ATM, PLK1, GSK3B, SFN, CDC20, CCND3, MYC |
Human T-cell leukemia virus 1 infection | Â | 21 | 1.49 | 5.40E-23 | KAT2A, CCND1, CDK4, CCND2, CREBBP, CCNE1, CDKN2C, EP300, CDK2, RB1, TP53, CCNA2, CDKN2B, ATM, BCL2L1, KAT5, TRRAP, PTEN, CDC20, CCND3, MYC |
Viral carcinogenesis | Â | 20 | 1.53 | 9.44E-23 | KAT2A, CCND1, CDKN1B, UBE3A, CDK4, MDM2, CCND2, CREBBP, CCNE1, EP300, CDK6, CDK2, RB1, TP53, CCNA2, SKP2, CDKN2B, USP7, CDC20, CCND3 |
p53 signaling pathway | Â | 16 | 1.84 | 2.22E-22 | CCND1, CDK4, MDM2, CCND2, CCNE1, CDK6, CDK2, TP53, ATM, BCL2L1, RCHY1, SFN, CCNG1, MDM4, PTEN, CCND3 |
Pathways in cancer | Â | 23 | 1.14 | 2.48E-18 | CCND1, CDKN1B, CDK4, MDM2, CCND2, CREBBP, CCNE1, EP300, CDK6, CDK2, RB1, TP53, CCNA2, SKP2, CDKN2B, BCL2L1, GSK3B, SP1, HSP90AA1, MAX, PTEN, CCND3, MYC |